Type 2 Diabetes: Clinical Breakdown: Pathophysiology, Insulin Resistance, Diagnostic Criteria, Microvascular/Macrovascular Complications, and Management Principles
A clinical reference on the dual defect of insulin resistance and beta-cell failure, the four diagnostic tests with prediabetes and diabetes thresholds, incretin and glucagon dysregulation, and microvascular and macrovascular complications.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This is the strongest of the three briefs. The dual-defect framing, the diagnostic table, the beta-cell and incretin sections and the complication categories are all correct and well organised. The notes below are the clinical safety points a reference like this needs alongside the mechanism.
- The diagnostic table is correct but incomplete in one respect that matters: in a person without symptoms, a single abnormal result does not make the diagnosis. It must be confirmed, either by repeating the same test on a new sample or by a second different test that is also abnormal. Where symptoms are classic and a random glucose is 200 mg/dL or above, no confirmation is needed. Acute illness, infection, steroids and surgery all raise glucose temporarily, so results taken during them are unreliable for diagnosis.
- A1C has failure modes the table does not flag. Anything that shortens red cell lifespan lowers it falsely, including haemolysis, recent blood loss, advanced kidney disease, pregnancy and recent transfusion; iron and B12 deficiency raise it. Some haemoglobin variants, more common in people of African, Mediterranean and South-East Asian descent, interfere with certain assays. Where A1C is unreliable, glucose measurements should be used instead.
- Distinguishing type 2 from type 1 should appear in any diagnostic section. Adult-onset autoimmune diabetes is frequently misclassified as type 2 at first. Normal weight, rapid onset, marked weight loss, ketones, autoimmune history or failure to respond to oral agents should prompt antibody testing and a C-peptide measurement, because the treatment differs entirely.
- The management section lists the drug classes accurately but as an undifferentiated set. Two of them now carry indications independent of glucose: SGLT2 inhibitors slow progression of chronic kidney disease and reduce heart failure hospitalisation, and GLP-1 receptor agonists reduce major cardiovascular events in people with established disease or high risk. In current practice, the presence of cardiovascular, kidney or heart failure disease steers the choice regardless of what the A1C is doing.
- Hypoglycemia risk differs sharply between the classes listed together here. Sulfonylureas and insulin cause it; metformin, SGLT2 inhibitors, GLP-1 agonists and DPP-4 inhibitors do not cause it on their own. Glyburide carries the highest risk in older adults. A reference that lists the classes should separate them on this point.
- Two class-specific hazards belong with the pharmacotherapy line. SGLT2 inhibitors can cause euglycemic diabetic ketoacidosis and are held during serious illness, prolonged fasting and before surgery. Metformin is reduced or avoided in significant kidney impairment, paused around contrast imaging, and can lower vitamin B12 on long-term use, which matters because the resulting neuropathy is mistaken for diabetic neuropathy.
- Glycemic targets are not stated. An A1C below 7 percent suits many non-pregnant adults, with tighter targets for those early in the disease and looser ones, 8 percent or above, for older adults, limited life expectancy, advanced complications or a history of severe hypoglycemia. Trials of very intensive control in long-standing diabetes with cardiovascular disease did not show the expected benefit, and one found increased mortality, so lower is not universally better.
- The complications section is accurate but omits the screening that detects each one early: a urine albumin-to-creatinine ratio annually for kidney disease, dilated eye examination from diagnosis, and an annual foot examination with sensation testing. It also omits fatty liver disease, which is very common in type 2 diabetes and now a leading cause of advanced liver disease.
- One addition to the pathophysiology, since the brief covers beta-cell exhaustion thoroughly. Some beta cells appear not to die but to dedifferentiate, losing their specialised function, and substantial weight loss restores a meaningful amount of function in some people, with remission most achievable within a few years of diagnosis. The progressive decline is real, but it is not uniformly permanent, and that changes the ambition of early treatment.
- Everything else in the brief is accurate: peripheral insulin resistance with progressive beta-cell secretory dysfunction as the dual defect; muscle, liver and adipose tissue failing to respond to normal insulin levels; impaired glucose uptake and failure to suppress hepatic gluconeogenesis; compensatory hyperinsulinemia followed by glucotoxicity, lipotoxicity, amyloid deposition and beta-cell loss; reduced GLP-1 and GIP incretin effect with inappropriate glucagon secretion; the diagnostic thresholds as tabulated; microvascular retinopathy, nephropathy and neuropathy alongside macrovascular atherosclerosis, coronary disease, stroke and peripheral artery disease; and multidisciplinary management combining nutrition therapy, activity, self-monitoring and targeted pharmacotherapy.
Download the PDF
Our reviewed pages on this
All source documents